PSTV 8-K — Smart Summary

On May 16, 2025, Plus Therapeutics, Inc. received a notice from Nasdaq that its common stock no longer complies with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), as the closing bid price fell below $1.00 per share for 30 consecutive business days. The company has an initial 180-day compliance period until November 12, 2025, to regain compliance, with a potential additional 180-day extension if certain conditions are met. The notice has no immediate effect on the listing or trading of the company's common stock on The Nasdaq Capital Market.

• On May 16, 2025, Plus Therapeutics, Inc. received a deficiency notice from The Nasdaq Stock Market LLC regarding non-compliance with Nasdaq Listing Rule 5550(a)(2), the Minimum Bid Requirement.
• The deficiency was triggered because the closing bid price of the company's common stock (ticker: PSTV) fell below $1.00 per share for 30 consecutive business days.
• The Nasdaq notice has no immediate effect on the listing or trading of the company's common stock on The Nasdaq Capital Market.
• Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the company has an initial compliance period of 180 calendar days, expiring November 12, 2025, to regain compliance.
• To regain compliance within the initial period, the closing bid price must meet or exceed $1.00 per share for a minimum of 10 consecutive business days prior to November 12, 2025.
• If compliance is not achieved by November 12, 2025, the company may be eligible for an additional 180 calendar days to regain compliance.
• To qualify for the additional compliance period, the company must meet the continued listing requirement for market value of publicly held shares and all other Nasdaq initial listing standards (except the Minimum Bid Requirement), and provide written notice of its intention to cure the deficiency, which may include effecting a reverse stock split if necessary.
• If Nasdaq staff determines the company will not be able to cure the deficiency, or if the company is not eligible for the additional compliance period, Nasdaq will provide notice that the common stock will be subject to delisting.
• Nasdaq rules permit the company to appeal any delisting determination by Nasdaq staff.
• The company intends to monitor the closing bid price of its common stock and may consider implementing available options to regain compliance with the Minimum Bid Requirement.